Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma

Figure 1 Clinical value of plasma miR-21 and miR-93 for esophageal squamous cell carcinoma patients. A: Expression of plasma miR-21 in esophageal squamous cell carcinoma (ESCC) patients; B: Expression of plasma miR-21 in patients with different T stages of ESCC ; C: Expression of plasma miR-21 in patients with different N stages of ESCC; D: Expression of plasma miR-21 in patients with different M stages of ESCC; E: Expression of plasma miR-21 in patients with different degrees of pathological differentiation of ESCC; F: Receiver operating characteristic (ROC) curves of plasma miR-21 for diagnosing T stage, N stage, M stage, and pathological differentiation of ESCC patients; G: Expression of plasma miR-93 in ESCC patients; H: Expression of plasma miR-93 in patients with different T stages of ESCC; I: Expression of plasma miR-93 in patients with different N stages of ESCC ; J: Expression of plasma miR-93 in patients with different M stages of ESCC; K: ROC curves of plasma miR-93 for diagnosing T stage, N stage, and M stage of ESCC patients. ^bP < 0.01 vs control group.

Figure 2 Predictive value of plasma miR-21 and miR-93 for radiotherapy and chemotherapy efficacy in esophageal squamous cell carcinoma patients. A: Expression of plasma miR-21 in esophageal squamous cell carcinoma (ESCC) patients before and after radiotherapy and chemotherapy; B: Expression of plasma miR-93 in ESCC patients before and after radiotherapy and chemotherapy; C: Expression of plasma miR-21 in ESCC patients with effective and ineffective response to radiotherapy and chemotherapy; D: Expression of plasma miR-93 in ESCC patients with effective and ineffective response to radiotherapy and chemotherapy; E: Receiver operating characteristic curves of plasma miR-21 and miR-93 for assessing radiotherapy and chemotherapy efficacy before radiotherapy and chemotherapy. ^bP < 0.01 vs control group.

Figure 3 Correlation of plasma miR-21 and miR-93 with 3-year overall survival of patients before radiotherapy and chemotherapy. A: Receiver operating characteristic (ROC) curve of miR-21 for assessing 3-year overall survival (OS); B: ROC curve of miR-93 for assessing 3-year OS; C: Correlation of miR-21 expression (≤ 5.60/> 5.60) with 3-year OS of esophageal squamous cell carcinoma (ESCC) patients; D: Correlation of miR-93 (≤ 3.87/> 3.87)with 3-year OS of ESCC patients.